Back to Stocks

AHCO

AdaptHealth Corp.
7 filings tracked
healthcaremedical devices and suppliesMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

AdaptHealth is undergoing a fundamental structural transformation, shifting from a traditional fee-for-service model to a recurring, capitation-driven healthcare platform.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a strategic pivot, AdaptHealth's financial results reveal a concerning trend of margin erosion. Adjusted EBITDA margins contracted from 16.4% to 14.8% year-over-year, as the cost of net revenue grew faster than total revenue.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every AHCO filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a classic trade-off between aggressive strategic growth and immediate financial stability. AdaptHealth is successfully growing its top line and expanding its footprint in at-risk capitation, but this growth is coming at a high cost. The company is effectively trading current cash flow and margin for the promise of future recurring revenue, a gamble that is currently being funded by a heavy debt load and a new credit facility. Investors are left to decide if the current margin compression is a temporary byproduct of a scaling phase or a systemic failure to control costs. While the debt refinancing provides a necessary runway, the combination of negative free cash flow and looming regulatory hurdles from CMS creates a precarious environment. The success of the company now depends on whether the capitated revenue slice can grow fast enough to offset the accelerating depreciation and labor expenses.

Selected Quarter

Core Takeaway

AdaptHealth is aggressively scaling at-risk capitated contracts to stabilize revenue, but this is causing a temporary spike in capex and labor costs.

Investor Lens

Whether the long-term LTV of capitated patients can offset the current surge in labor and equipment depreciation.

Watch Next

The impact of the CMS 6-month enrollment moratorium on new location and acquisition growth.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.20Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 5

Adjusted EBITDA margin declined from 16.4% to 14.8% due to rising labor and depreciation costs.

margin compression
60%
bullishMay 5

Refinanced debt into a new 2026 Credit Facility extending maturities to April 2031.

debt restructure
70%
bearishMay 5

CMS imposed a 6-month moratorium on certain DMEPOS supplier enrollments, risking growth initiatives.

regulatory action
50%
bearishMay 5

Net loss attributable to the company increased to $16.0 million from $7.2 million YoY.

earnings miss
40%
bearishMay 5

Adjusted EBITDA margin declined from 16.4% to 14.8% due to rising labor and depreciation costs.

margin compression
60%
bullishMay 5

Refinanced debt into a new 2026 Credit Facility extending maturities to April 2031.

debt restructure
70%
bearishMay 5

CMS imposed a 6-month moratorium on certain DMEPOS supplier enrollments, risking growth initiatives.

regulatory action
50%
bearishMay 5

Net loss attributable to the company increased to $16.0 million from $7.2 million YoY.

earnings miss
40%
bearishMay 5

Adjusted EBITDA margin declined from 16.4% to 14.8% due to rising labor and depreciation costs.

margin compression
60%
bullishMay 5

Refinanced debt into a new 2026 Credit Facility extending maturities to April 2031.

debt restructure
70%
bearishMay 5

CMS imposed a 6-month moratorium on certain DMEPOS supplier enrollments, risking growth initiatives.

regulatory action
50%
bearishMay 5

Net loss attributable to the company increased to $16.0 million from $7.2 million YoY.

earnings miss
40%
bearishMay 5

Adjusted EBITDA margin declined from 16.4% to 14.8% due to rising labor and depreciation costs.

margin compression
60%
bullishMay 5

Refinanced debt into a new 2026 Credit Facility extending maturities to April 2031.

debt restructure
70%
bearishMay 5

CMS imposed a 6-month moratorium on certain DMEPOS supplier enrollments, risking growth initiatives.

regulatory action
50%
bearishMay 5

Net loss attributable to the company increased to $16.0 million from $7.2 million YoY.

earnings miss
40%
bearishMay 5

Adjusted EBITDA margin declined from 16.4% to 14.8% due to rising labor and depreciation costs.

margin compression
60%
bullishMay 5

Refinanced debt into a new 2026 Credit Facility extending maturities to April 2031.

debt restructure
70%
bearishMay 5

CMS imposed a 6-month moratorium on certain DMEPOS supplier enrollments, risking growth initiatives.

regulatory action
50%
bearishMay 5

Net loss attributable to the company increased to $16.0 million from $7.2 million YoY.

earnings miss
40%
bearishMay 5

Adjusted EBITDA margin declined from 16.4% to 14.8% due to rising labor and depreciation costs.

margin compression
60%
bullishMay 5

Refinanced debt into a new 2026 Credit Facility extending maturities to April 2031.

debt restructure
70%
bearishMay 5

CMS imposed a 6-month moratorium on certain DMEPOS supplier enrollments, risking growth initiatives.

regulatory action
50%
bearishMay 5

Net loss attributable to the company increased to $16.0 million from $7.2 million YoY.

earnings miss
40%
bearishMay 5

Adjusted EBITDA margin declined from 16.4% to 14.8% due to rising labor and depreciation costs.

margin compression
60%
bullishMay 5

Refinanced debt into a new 2026 Credit Facility extending maturities to April 2031.

debt restructure
70%
bearishMay 5

CMS imposed a 6-month moratorium on certain DMEPOS supplier enrollments, risking growth initiatives.

regulatory action
50%
bearishMay 5

Net loss attributable to the company increased to $16.0 million from $7.2 million YoY.

earnings miss
40%

Filing History

10-QMay 5, 2026
Expand Sequence

The Q1 2026 filing presents a classic trade-off between aggressive strategic growth and immediate financial stability. AdaptHealth is successfully growing its top line and expanding its footprint in at-risk capitation, but this growth is coming at a high cost. The company is effectively trading current cash flow and margin for the promise of future recurring revenue, a gamble that is currently being funded by a heavy debt load and a new credit facility. Investors are left to decide if the current margin compression is a temporary byproduct of a scaling phase or a systemic failure to control costs. While the debt refinancing provides a necessary runway, the combination of negative free cash flow and looming regulatory hurdles from CMS creates a precarious environment. The success of the company now depends on whether the capitated revenue slice can grow fast enough to offset the accelerating depreciation and labor expenses.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.